{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:08:58Z","timestamp":1794107338174,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajo.2025.08.024","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T20:50:05Z","timestamp":1755550205000},"page":"326-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Potency Matters: The Role of Statin Intensity in Modulating Risk for Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-2651","authenticated-orcid":false,"given":"Zain S.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Z.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2830-9832","authenticated-orcid":false,"given":"Jawad","family":"Muayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Loya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Nembhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-6782","authenticated-orcid":false,"given":"Ahmed B.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajo.2025.08.024_bib0001","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ophtha.2014.03.013","article-title":"Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene\/environment susceptibility study","volume":"121","author":"Jonasson","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.024_bib0002","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.024_bib0003","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u24c7","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.024_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.ajo.2025.08.024_bib0006","first-page":"1","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pr"},{"key":"10.1016\/j.ajo.2025.08.024_bib0007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ebiom.2016.01.033","article-title":"Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment","volume":"5","author":"Vavvas","year":"2016","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.ajo.2025.08.024_bib0008","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.ophtha.2015.08.028","article-title":"The Association of statin use with age-related macular degeneration progression: the age-related eye disease study 2 report number 9","volume":"122","author":"SN","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.024_bib0009","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000003398","article-title":"Statin use and the incidence of age-related macular degeneration: a meta-analysis","volume":"42","author":"Eshtiaghi","year":"2022","journal-title":"Retina"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.08.024_bib0010","first-page":"S179","article-title":"Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ajo.2025.08.024_bib0011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jamacardio.2022.2851","article-title":"Statin usage in primary prevention-comparing the USPSTF recommendations with the AHA\/ACC\/multisociety guidelines","volume":"7","author":"Stone","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"24","key":"10.1016\/j.ajo.2025.08.024_bib0012","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajo.2025.08.024_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2024.01.016","article-title":"Association of primary open-angle glaucoma with diabetic retinopathy among patients with type 1 and type 2 diabetes: a large global database study","author":"Chauhan","year":"2024","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2025.08.024_bib0014","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.08.024_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2024.02.023","article-title":"Association of ocular manifestations of Marfan syndrome with cardiovascular complications","volume":"264","author":"Tran","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.024_bib0016","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamaophthalmol.2024.1822","article-title":"Melatonin and risk of age-related macular degeneration","volume":"142","author":"Jeong","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.08.024_bib0017","article-title":"Curcuma-based nutritional supplements and risk of age-related macular degeneration","volume":"24","author":"Alsoudi","year":"2024","journal-title":"JAMA Ophthalmol Publ online Oct"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.024_bib0018","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000003398","article-title":"Statin use and the incidence of age-related macular degeneration: a meta-analysis","volume":"42","author":"Eshtiaghi","year":"2022","journal-title":"Retina (Phila Pa,)"},{"issue":"3","key":"10.1016\/j.ajo.2025.08.024_bib0019","first-page":"581","article-title":"Can HMG Co-a reductase inhibitors (\u201cStatins\u201d) slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS)","volume":"3","author":"Guymer","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"12","key":"10.1016\/j.ajo.2025.08.024_bib0020","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.ophtha.2009.06.055","article-title":"Complications of age-related macular degeneration prevention trial (CAPT) research group. Statin use and the incidence of advanced age-related macular degeneration in the complications of age-related macular degeneration prevention trial","volume":"116","author":"Maguire","year":"2009","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252878","article-title":"Statins and the progression of age-related macular degeneration in the United States","volume":"16","author":"Ludwig","year":"2021","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.ajo.2025.08.024_bib0005","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/eurjpc\/zwac103","article-title":"Burden and predictors of Statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020","volume":"29","author":"Chobufo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.024_bib0022","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1038\/s41598-017-02407-7","article-title":"Atorvastatin promotes phagocytosis and attenuates pro-inflammatory response in human retinal pigment epithelial cells","volume":"7","author":"Tian","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ajo.2025.08.024_bib0023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1167\/iovs.65.6.38","article-title":"Unveiling statins and genetics in age-related macular degeneration: the Coimbra eye study-report 9","volume":"65","author":"Barreto","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.024_bib0024","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaophthalmol.2024.1584","article-title":"Effect of low-dose aspirin on the course of age-related macular degeneration: a secondary analysis of the ASPREE randomized clinical trial","volume":"142","author":"Robman","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.024_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2007.02.047","article-title":"Statin use and the five-year incidence and progression of age-related macular degeneration","volume":"144","author":"Klein","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.024_bib0026","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.11.021","article-title":"Statins and the long-term risk of incident age-related macular degeneration: the blue mountains eye study","volume":"143","author":"Tan","year":"2007","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425004301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425004301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:17:53Z","timestamp":1779855473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425004301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"alternative-id":["S0002939425004301"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.08.024","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potency Matters: The Role of Statin Intensity in Modulating Risk for Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}